{"preliminary_commentary":{"by_channel":{"x_thread":9,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03127631\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":null,"indication":"prostate cancer","name":"RADICALPC","nct_id":"NCT03127631","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=radicalpc-nct03127631. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RADICALPC","arms":[{"description":"The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label statins, ACE-I, and other antihypertensive medications where appropriate.","label":"Randomized - Intervention","type":"ACTIVE_COMPARATOR"},{"description":"The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.","label":"Randomized - Control","type":"NO_INTERVENTION"}],"collaborators":["Prostate Cancer Canada","Canadian Cancer Society (CCS)","Tolmar Inc."],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Prostate Cancer","Cardiovascular Disease"],"enrollment":{"count":5000,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Nutrition","otherNames":[],"type":"BEHAVIORAL"},{"name":"Exercise","otherNames":[],"type":"BEHAVIORAL"},{"name":"Smoking cessation","otherNames":[],"type":"BEHAVIORAL"},{"name":"Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)","otherNames":[],"type":"DRUG"},{"name":"ACE inhibitor","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-02","lead_sponsor":"McMaster University","official_title":"The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A Randomized Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).","timeFrame":"3-5 years"},{"measure":"Time to the first occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure.","timeFrame":"3-5 years"}],"references":[{"citation":"Leong DP, Higano C, Cano Garcia C, Fradet V, Siemens DR, Niazi T, Shayegan B, Guha A, Cirne F, Selvanayagam JB, Violette PD, Valle FH, Lavallee LT, Duceppe E, Anderson P, Xavier D, Lopez-Lopez JP, Villareal Trujillo N, Galapo Kann A, Piccoli RK, Mourtzakis M, Sarid D, Narasimha S, Luke PPW, Hajjar LA, Lukka H, Klotz L, Balasubramanian K, Mian R, Agapay S, Rangarajan S, Karampatos S, Ng KKH, Avezum A, Devereaux PJ, Pinthus JH; RADICAL PC Investigators. Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial. JAMA Intern Med. 2026 Aug 30. doi: 10.1001/jamainternmed.2026.4773. Online ahead of print.","pmid":"42669035","type":"DERIVED"},{"citation":"Dahan J, Pinthus J, Delouya G, Taussky D, Duceppe E, de Jesus A, Leong D. Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio. BMC Urol. 2024 Oct 16;24(1):226. doi: 10.1186/s12894-024-01617-2.","pmid":"39407194","type":"DERIVED"},{"citation":"Savija N, Leong DP, Pinthus J, Karampatos S, Shayegan B, Mian R, Rangarajan S, Fradet V, de Souza RJ, Mente A, Dehghan M. Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Curr Dev Nutr. 2021 Aug 12;5(11):nzab106. doi: 10.1093/cdn/nzab106. eCollection 2021 Nov.","pmid":"34870071","type":"DERIVED"}],"start_date":{"date":"2015-10-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03127631"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/radicalpc-nct03127631"}